We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Adam’s Secret Draws Warning Letter for Misbranded Drugs

Adam’s Secret Draws Warning Letter for Misbranded Drugs

January 23, 2023

Undisclosed tadalafil and sildenafil in a “male enhancement” supplement and lorcaserin — a controlled substance that has been withdrawn from the U.S. market — hidden in a weight-loss supplement, have earned Adam’s Secret USA an FDA warning letter.

These products, which were sold online, are considered both unapproved new drugs and misbranded drugs, and can’t be sold in the U.S., the letter says.

The New Jersey-based company has been dinged before over this issue, most recently in July 2022. The FDA issued a public warning not to buy Adam’s Secret Extra Strength Amazing Black capsules after a lab analysis showed they contained tadalafil. Analyses of other Adam’s Secret sexual function products commenced, with several issues found.

The products included Adam’s Secret Extra Strength Purple and Adam’s Secret Extra Strength 2000, both of which contain a combination of the phosphodiesterase type-5 (PDE-5) inhibitors tadalafil and sildenafil. Sildenafil is the active ingredient in Viagra and tadalafil is the active ingredient in Cialis.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Wandercraft Walking Robotic Exoskeleton Gets FDA Clearance for Stroke Rehab

  • Better Business Bureau Flags Novartis Advertising for Kisqali

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing